Curriculum Vitae

DR. CHEONG CHIN SUM

Medical Lecturer
  • Department of Medicine
    Faculty of Medicine

AREAS OF EXPERTISE

  • HAEMATOLOGY

ACADEMIC QUALIFICATION

  • M.S(INTERNAL MED), (Internal Medicine)
    Universiti Malaya (UM)
  • MBBS, (Medicine and Surgery)
    Universiti Malaya (UM)

MEMBERSHIPS

  • MALAYSIAN SOCIETY OF HAEMATOLOGY, LIFE MEMBER
    Since 2019 (National)
  • NATIONAL SPECIALIST REGISTER, MEMBER
    2018 to 2022 (National)

PUBLICATIONS

Article in Journal
WoS
  1. Sulaiman, Noor Yuhyi; Anuar, Nur Adila; Arshad, Normala; Cheong, Chin Sum; Liong, Chee Chiat; Khairullah, Shasha; Chin, Edmund Fui Min; Bee, Ping Chong; Sam, I. Ching; Iyadorai, Thevambiga; Gan, Gin Gin (2023). CMV Infection Post Allogeneic Hematopoietic Stem Cell Transplantation in a Resource Limited Country, INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION. . doi:10.1007/s12288-023-01655-0
  2. Cheong, Chin Sum; Tan, Sen Mui; Ng, Soo Chin; Ong, Tee Chuan; Abd Kadir, Sharifah Shahnaz Syed; Ho, Kim Wah; Teh, Alan; Rahman, Haris Abdul; Bee, Ping Chong; Aoki, Naomi; Chen, Pin-Yen; Wood, Erica M.; Spencer, Andrew; Moore, Elizabeth M.; Chng, Wee Joo; Gan, Gin Gin (2022). Real World Treatment Outcomes for Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant in Different Income Countries within Asia Pacific Region, BLOOD. 140, 12541-12543. doi:10.1182/blood-2022-164888
  3. Ahmad, S. B., Cheong, C. S., Lim, S. Y., Rahmat, K., FaizatulIzzaRozalli, Sekaran, S. D., Sulaiman, H., Ponnam-palavanar, S., Lim, K. S., Tan, C. T. (2016). Bilateral thalamic internal medullary lamina involvement in a case of dengue encephalitis. Neurology Asia, 21(4), 375-379.
Scopus
  1. Cheong C.S., Aziz T.A.H.T.K., Anuar N.A., Bee P.C., Chin E.F.M., Khairullah S., Liong C.C., Zamri Y., Gan G.G. (2024). Treatment Pattern and Outcome of Newly Diagnosed Multiple Myeloma Patients in a Resource-Limited Setting, Asian Pacific journal of cancer prevention : APJCP. 25(2), 595-601. doi:10.31557/APJCP.2024.25.2.595
  2. Cheong, C. S., Gan, G. G., Chen, T. M., Lim, C. C., Nadarajan, V. S., Bee, P. C. (2016). Parvovirus B19 associated haemophagocytic lymphohistiocytisis in hereditary spherocytosis patient: A case report. Journal of Health and Translational Medicine, 19(2), 12-16.
Article in Proceeding
  1. CC Liong, T. Iyadorai, N. Hussein, CS Cheong, ST Tay, RD. Velayuthan, S. Khairullah, NA. Anuar, FM Chin, PC Bee, GG Gan (2021, August 5-7) 18th Annual Scientific Meeting of Malaysian Society of Haematology, Virtual.
  2. Karajacob A.S., Azizan N., Al-Maleki A. R, Goh J., Ponnampalavanar S., Loke M.F., Himratul-AznitaW.H., Vaithilingam R.D.,Vadivelu J., Kallarakkal T.G., Zainuddin S.I., Khor H.M., Ho G.F., Tan L.T., Ong H.C., Cheong, C.S., Tay S.T. (2021, August 6-8) Isolation, speciation and antifungal susceptibility testing of Candida yeasts from oral thrush patients in a teaching hospital [Poster Presentation] Congress of the International Society for Human and Animal Mycology Asia Fungal Working Group, Virtual.
  3. Liong C.C., Iyadorai T., Hussein N., Cheong C.S., Tay S.T., Velayuthan R.D., Gan G.G. (2021, August 6-8) Prevalence of invasive fungal infection in patients with acute leukemia in a teaching hospital in Malaysia [Poster Presentation] Congress of the International Society for Human and Animal Mycology Asia Fungal Working Group, Virtual.

RESEARCH PROJECT

National
  1. 2020 - 2028, Novartis Corporation (M) Sdn. Bhd.
    A randomized, double-blind, placebo-controlled phase III multi-center study of azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) ( Co-Researcher)
  2. 2021 - 2025, Johnson & Johnson Sdn. Bhd.
    A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Clinical Outcomes, Antiviral Activity, Safety, Tolerability, Pharmacokinetics, and Pharmacokinetics/Pharmacodynamics of JNJ-53718678 in Adult and Adolescent Hematopoietic Stem Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Upper Respiratory Tract ( Co-Researcher)
  3. 2021 - 2025, F2G Ltd
    A Phase III, adjudicator-blinded, randomised study to evaluate the efficacy and safety of treatment with olorofim versus treatment with AmBisome followed by standard of care (SOC) in patients with invasive fungal disease (IFD) caused by Aspergillus species ( Co-Inventor)
  4. 2022 - 2025, NS Pharma, Inc
    A Phase 2b, Open-label, Multicenter, Randomized, Controlled, 2-Arm Study to Assess the Efficacy and Safety of Orally Administered NS-018 versus Best Available Therapy in Subjects with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelet Count <50,000/ L) ( Co-Researcher)
Private
  1. 2023 - 2027, Novartis Corporation (Malaysia) Sdn. Bhd.
    A PHASE IIIB, MULTI-CENTER, OPEN-LABEL, RANDOMIZED STUDY OF TOLERABILITY AND EFFICACY OF ORAL ASCIMINIB VERSUS NILOTINIB IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE ( Co-Researcher)
  2. 2021 - 2024, Private Funding
    Assessing Immune Responses To Covid-19 Vaccination Among Patients With Chronic Myeloid Leukemia- Phase 1 ( Co-Researcher)
  3. 2023 - 2024, Private Funding
    Developing A Masterclass In Chronic Myeloid Leukaemia ( Co-Researcher)
International
  1. 2022 - 2027, CONSTELLATION PHARMACEUTICAL, INC
    A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients ( Co-Researcher)
  2. 2019 - 2024, Monash University
    Asia Pacific Myeloma and related diseases registry ( Co-Researcher)
  3. 2023 - 2024, Janssen Research & Development LLC
    EFFICACY AND SAFETY OF M281 IN ADULTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH A LONG-TERM OPEN-LABEL EXTENSION ( Co-Researcher)
  4. 2022 - 2023, BioCryst Pharmaceuticals, Inc
    A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral BCX9930 Monotherapy for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (BioCryst Protocol BCX9930-203) ( Co-Researcher)
  5. 2022 - 2023, AstraZeneca Sdn. Bhd.
    A Multicenter Retrospective Study To Understand The Clinical Characteristics, Treatment Pathway And Resource Utilization For Patients With Chronic Lymphocytic Leukemia (CLL). ( Co-Researcher)
  6. 2019 - 2022, INTERNATIONAL MYELOMA FOUNDATION
    Randomized Phase 3 study of Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) versus Pomalidomide-Dexamethasone (PD) in relapse or refractory myeloma. An AMN study ( Co-Researcher)
  7. 2019 - 2022, INTERNATIONAL MYELOMA FOUNDATION
    Randomized Phase 3 study of Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) versus Pomalidomide-Dexamethasone (PD) in relapse or refractory myeloma. An AMN study ( Co-Researcher)

PAPER PRESENTED

INVITED SPEAKER
  1. Overview of Multiple Myeloma, Myeloma Support Group Forum, Myeloma Support Group Universiti Malaya Medical Center (National) (12 Dec 2023 - 12 Dec 2023)
  2. Importance of Iron Chelation and Iron Management, Thalassaemia Education Camp - for Patients and Parents of UMMC/ PPUM, THASUH (National) (18 Mar 2023 - 18 Mar 2023)
  3. Case Presentation, GRAFfiTi Conference 2.0 and GvHD launch, Novartis Malaysia (International) (09 Mar 2023 - 09 Mar 2023)
  4. Optimizing Treatment Management in Chronic GvHD Case Presentation, 2nd GvHD Webinar, Novartis (National) (14 Jul 2022 - 14 Jul 2022)
POSTER PRESENTER
  1. Long Term Outcome of Multiple Myeloma Patients Post Autologous Stem Cell Transplant in Klang Valley, 27th Congress of Asia-Pacific Blood and Marrow Transplantation Group, Asia-Pacific Blood and Marrow Transplant Group (International) (06 Oct 2022 - 09 Oct 2022)
  2. Immune Response of Chronic Myeloid Leukemia Patients Towards SARS-COV-2 Vaccination, 19th Malaysian Society of Haematology Scientific Meeting 2022, Malaysian Society of Haematology (National) (09 Aug 2022 - 11 Aug 2022)
  3. Adverse Events from SARS-COV-2 Vaccination Among Patients with Chronic Myeloid Leukemia in Malaysia, 19th Malaysian Society of Haematology Scientific Meeting 2022, Malaysian Society of Haematology (National) (09 Aug 2022 - 11 Aug 2022)
  4. Long Term Treatment Outcome of Multiple Myeloma Patients Post Autologous Stem Cell Transplantation in Klang Valley Hospitals, 19th Malaysian Society of Haematology Scientific Meeting 2022, Malaysian Society of Haematology (National) (09 Aug 2022 - 11 Aug 2022)
  5. Rituximab and Lenalidomide for Relapsed/ Refractory Diffuse Large B Cell Lymphoma: A Case Series, 18th Malaysian Society of Haematology Annual Scientific Meeting, Malaysian Society of Haematology (National) (05 Aug 2021 - 07 Aug 2021)
  6. Daratumumab Combination Therapy for Relapsed/ Refractory Multiple Myeloma: A Case Series, 18th Malaysian Society of Haematology Annual Scientific Meeting, Malaysian Society of Haematology (National) (05 Aug 2021 - 07 Aug 2021)

ACADEMIC/PROF. SERVICES

Evaluation
  1. (2023) Pemeriksa Kertas Saq Bagi Ujian Modul Penyakit Manusia Tahun Ketiga Ijazah Sarjana Muda Pembedahan Pergigian Sesi 2022/ 2023 Fakulti Pergigian, University, (Internal Examiner)
  2. (2023) Ahli Jawatankuasa Pemeriksa Dalam Semester 2, Sesi 2022/ 2023 Bagi Program Ijazah Sarjana Muda Sains Kejururawatan, University, (Internal Examiner)
  3. (2022) Peperiksaan Profesional Ijazah Sarjana Muda Pembedahan Pergigian (Tahun 3), Sesi 2021/2022, University, (Internal Examiner)
  4. (2021) Ummp 3.1 End of Posting Class of 2018/ 2023: Suplementary Posting, University, (Internal Examiner)
  5. (2021) Ummp 3.3 End of Posting Class of 2016/ 2021: Posting L, University, (Internal Examiner)
  6. (2021) Ummp 3.1 End of Posting Class of 2018/ 2023: Posting B, University, (Internal Examiner)
Contribution to external organisation
  1. (2024) Panel Pakar Penasihat Pihak Berkuasa Kawalan Dadah Kementerian Kesihatan Malaysia, National, (Expert Advisor)

SUPERVISION

Postgraduate Student
  1. (2021) -, MUHAMMAD ARIFF SHAHRIMAN BIN MARZUKHI
  2. (2021) -, UMA DEVI MARKANDAN

TEACHING

Master
  1. (2022) NA - Mmed - Masters in Internal Medicine
  2. (2021) - - Master of Internal Medicine (Mmed)
Bachelor
  1. (2022) NA - Ummp 3.3 Posting J (Stream 3)
  2. (2022) NA - Ummp 3.3 Posting K (Stream 2)
  3. (2022) NA - Ummp 3.3 Posting L (Stream 1)
  4. (2022) NA - Ummp Stage 3.1 2021/2022 Stream 3, Posting B
  5. (2022) NA - Ummp Stage 3.3 Posting I (Stream 4)
  6. (2022) DIA3012 - Human Diseases (General Medicine)
  7. (2021) MIA 2001 - Universiti Malaya Medical Programme (Ummp)
  8. (2021) - - University Malaya Medical Programme (Ummp) Stage 3.1
  9. (2021) - - University Malaya Medical Programme (Ummp) Stage 3.3

COURSE ATTENDED

Internal / External Course
INTERNAL COURSE- ORGANIZED BY PTJ
  1. EMERALD TEACHING AND LEARNING 2022, Online (21 Feb 2022 - 04 Mar 2022)
CONFERENCE
  1. 27TH ANNUAL MEETING OF ASIA-PACIFIC BLOOD AND MARROW TRANSPLANT GROUP, Grand Hyatt Kochi Bolgatty, India (06 Oct 2022 - 10 Oct 2022)
  2. 2022 ASIAN MYELOMA NETWORK MASTER CLASS AND 2022 ASIAN MYELOMA NETWORK MYELOMA SUMMIT, Voco Hotel and Shangri La Hotel, Singapore (12 Oct 2022 - 16 Oct 2022)
  3. 20TH MALAYSIAN SOCIETY OF HAEMATOLOGY ANNUAL SCIENTIFIC MEETING, Holiday Inn, Melaka (10 Mar 2023 - 11 Mar 2023)
  4. IMF ASIAN MYELOMA NETWORK 3RD MASTER CLASS, Shangri La Hotel, Bangkok, Thailand (18 Oct 2023 - 21 Oct 2023)
  5. HEMATOLOGY IMMERSION PROGRAM 2023, Courtyard by Marriott Bangkok (17 Nov 2023 - 20 Nov 2023)